Entering text into the input field will update the search result below

Karyopharm Therapeutics Inc. (KPTI) CEO Richard Paulson on Q1 2021 Results - Earnings Call Transcript

SA Transcripts profile picture
SA Transcripts

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Q1 2021 Results Earnings Conference Call May 3, 2021 8:30 AM ET

Company Participants

Ian Karp - Senior Vice President, Investor and Public Relations

Richard Paulson - President and Chief Executive Officer

Michael Kauffman - Co-Founder, Senior Clinical Advisor and Board Member

Michael Mason - Chief Financial Officer

John Demaree - Chief Commercial Officer

Stephen Mitchener - Chief Business Officer

Conference Call Participants

Brian Abrahams - RBC Capital Markets

Maury Raycroft - Jefferies

Peter Lawson - Barclays

Eric Joseph - JPMorgan

David Lebowitz - Morgan Stanley

Jonathan Chang - SVB Leerink

Ed White - H.C. Wainwright

Colleen Kusy - Baird

Arlinda Lee - Canaccord


Good morning. My name is Jason, and I will be your conference operator for today. At this time, I’d like to welcome everyone to Karyopharm Therapeutics' First Quarter 2021 Financial Results Conference Call. There will be a question-and-answer session to follow. Please be advice that this call is being recorded at the company's request.

I would now like to turn the call over to Mr. Ian Karp, Karyopharm's Senior Vice President, Investor and Public Relations.

Ian Karp

Great. Thank you. And thank you all for joining us on today's conference call, to discuss Karyopharm's first quarter financial results and business update. And let me be the first one to officially welcome our President and Chief Executive Officer, Mr. Richard Paulson to our quarterly earnings call. This is Ian Karp, and today in addition to both Michael Kauffman, and Richard Paulson, I am also joined by Mr. Mike Mason, our Chief Financial Officer; Mr. John Demaree, Chief Commercial Officer; Mr. Stephen Mitchener, Chief Business Officer.

On the call today, Michael will provide an overview of key recent corporate developments and an update on our commercial progress, followed by an update on one of our

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.